Endeavour Cell

Endeavour Cells is a Danish biotechnology company specializing in the development of advanced stem cell therapies for neurodevelopmental and inflammatory conditions. As a key investment arm of Endeavour Invest, the company holds a majority stake in Cell2Cure ApS and maintains sublicensing rights for allogeneic adipose tissue-derived mesenchymal stromal/stem cells (ASCs). Its clinical pipeline is primarily focused on treating Autism Spectrum Disorder (ASD), ADHD, and associated conditions like leaky gut syndrome, with active Phase I/II clinical trials underway. By leveraging a scalable, GMP-grade cell platform, Endeavour Cells aims to provide off-the-shelf regenerative treatments that address the underlying causes of complex diseases.